Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol.

Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol.

<h4>Background</h4>Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease prone to widespread metastatic dissemination and characterized by a desmoplastic stroma that contributes to poor outcomes. Fibroblast activation protein (FAP)-expressing Cancer-Associated Fibroblasts (CAFs) ar...

Full description

Saved in:
Bibliographic Details
Main Authors: Aashna Karbhari, Sherly Mosessian, Kamaxi H Trivedi, Frank Valla, Mark Jacobson, Mark J Truty, Nandakumar G Patnam, Diane M Simeone, Elcin Zan, Tracy Brennan, Hongli Chen, Phillip H Kuo, Ken Herrmann, Ajit H Goenka
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0294564
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://doi.org/10.1371/journal.pone.0294564

Similar Items